Last update 27 Jun 2024
JSKN-003
Last update 27 Jun 2024
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms JSKN 003, JSKN-003, JSKN003 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Structure
Boost your research with our XDC technology data.
login
or
Related
5
Clinical Trials associated with JSKN-003A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
JSKN003对比研究者选择化疗治疗HER2低表达复发/转移性乳腺癌的随机、开放、平行对照、多中心III期临床研究
[Translation] A randomized, open, parallel-controlled, multicenter phase III clinical study of JSKN003 versus investigator-selected chemotherapy in the treatment of recurrent/metastatic breast cancer with low HER2 expression
Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors
100 Clinical Results associated with JSKN-003
Login to view more data
100 Translational Medicine associated with JSKN-003
Login to view more data
100 Patents (Medical) associated with JSKN-003
Login to view more data
100 Deals associated with JSKN-003
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2-Low Breast Carcinoma | Phase 3 | CN | 14 Nov 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 02 Mar 2023 | |
| Metastatic Solid Tumor | Phase 1 | AU | 02 Sep 2022 | |
| HER2 Positive Solid Tumors | IND Approval | CN | 13 Nov 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Advanced Malignant Solid Neoplasm HER2-expressing | HER2-mutant | 46 | xnbiowkfgo(vloyauflpd) = No pts experienced DLT or interstitial lung disease, and no TRAE led to death or discontinuation atlvhjzucd (fuusomesaa ) View more | Positive | 24 May 2024 | ||
Phase 1 | Solid tumor ERBB2 Mutation (Activating) | HER2 Expression | 32 | cavbtsgvgy(crytkgfopb) = not been reached. ljgxriwwut (aqqetpxhiv ) View more | Positive | 05 Apr 2024 | ||
Phase 1 | HER2-Expressing Cancers HER2 Expression | 32 | kbrsdbggon(flehtmbnur) = qqmrnfhbpx irlnqgmztm (tnbrlypyfz ) View more | Positive | 16 Nov 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free